The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients [0.03%]
肾功能对不适合移植的多发性骨髓瘤初始治疗的影响
Yutaka Shimazu,Junya Kanda,Teruhito Takakuwa et al.
Yutaka Shimazu et al.
The prognosis for multiple myeloma (MM) patients has improved with the advent of new drugs, but the prognosis with renal impairment (RI) is poor. The choice of treatment in such cases is critical, but there are no set criteria. We examined ...
Intratubular cytoplasmic AL amyloidosis associated with amyloidogenic and crystalline light chain cast nephropathy [0.03%]
与淀粉样变性和结晶性轻链管型肾病相关的管腔内胞质AL淀粉样变性
François Husser,Nizar Joher,Vincent Audard et al.
François Husser et al.
Risk and impact of cytomegalovirus infection in lymphoma patients treated with bendamustine [0.03%]
苯达莫斯汀治疗淋巴瘤患者发生巨细胞病毒感染的风险与影响
Jen-Pei Huang,Chiu-Mei Yeh,Ya-Wen Gong et al.
Jen-Pei Huang et al.
Bendamustine is used to treat lymphoma with excellent efficacy but is known for its immunosuppressive effect. Cytomegalovirus (CMV) reactivation after bendamustine use has been reported. We aim to address the impact of CMV infection in lymp...
Allogeneic hematopoietic cell transplantation from alternative donors in acute myeloid leukemia [0.03%]
急性髓系白血病患者接受非亲缘供者的异基因造血细胞移植
Junichi Sugita,Kaoru Morita,Takaaki Konuma et al.
Junichi Sugita et al.
Allogeneic hematopoietic cell transplantation (HCT) potentially provides a cure for patients with acute myeloid leukemia (AML) who are unlikely to be cured with chemotherapy alone. Previously, human leukocyte antigen (HLA)-matched related d...
Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis [0.03%]
BTK抑制剂阿卡替尼或伊布替尼治疗慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者的三年心血管和非心血管不良事件：真实世界分析
Rafael Amorim Belo Nunes,Álvaro Avezum,Mariana de Oliveira Marques et al.
Rafael Amorim Belo Nunes et al.
Bruton tyrosine kinase (BTK) inhibitors play an important role in targeted treatment of B-cell lymphoproliferative disorders. However, adverse events may limit the proper course of treatment in many patients. The purpose of this study is to...
Multicenter Study
Annals of hematology. 2024 Nov;103(11):4613-4620. DOI:10.1007/s00277-024-05921-7 2024
A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold? [0.03%]
维奈克拉治疗不适用强化疗方案的急性髓系白血病患者的系统性综述：闪光点都是金子吗？
Antonio Solana-Altabella,Rebeca Rodríguez-Veiga,David Martínez-Cuadrón et al.
Antonio Solana-Altabella et al.
Acute myeloid leukemia (AML) is an aggressive hematological disease that mainly affects elderly patients. Following the randomized VIALE-A trial, current standard treatment in patients who are not candidates for intensive chemotherapy consi...
Diagnostic performance of liver stiffness as marker of liver involvement in systemic immunoglobulin light chain (AL) amyloidosis [0.03%]
肝脏淀粉样变性肝弹性硬度诊断标准的性能研究
Anne F Brunger,Hendrea S A Tingen,Johan Bijzet et al.
Anne F Brunger et al.
Objective: To investigate the diagnostic performance of liver stiffness for detecting liver involvement in immunoglobulin light chain (AL) amyloidosis. Me...
A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis [0.03%]
阿那格雷仿制药治疗初级骨髓纤维化患者三期临床试验
Ghaith Abu-Zeinah,Albert Qin,Harinder Gill et al.
Ghaith Abu-Zeinah et al.
Primary myelofibrosis (PMF) is the most aggressive of the myeloproliferative neoplasms and patients require greater attention and likely require earlier therapeutic intervention. Currently approved treatment options are limited in their sel...
Clinical Trial
Annals of hematology. 2024 Sep;103(9):3573-3583. DOI:10.1007/s00277-024-05912-8 2024
IRF4 dysregulation in chronic myelomonocytic leukemia: another brick in the wall of myelodysplastic/myeloproliferative neoplasms [0.03%]
慢性嗜酸性粒细胞白血病中IRF4的失调：低级/骨髓增生性肿瘤的另一因素
Francesco Tarantini,Cosimo Cumbo,Elisa Parciante et al.
Francesco Tarantini et al.
CD19 CAR T-cell therapy in relapsed TCF3-HLF-positive B-cell acute lymphoblastic leukemia [0.03%]
复发性TCF3-HLF阳性B细胞急性淋巴细胞白血病的CD19 CAR-T细胞治疗
Yao Yao,Jin Zhou,Yanting Li et al.
Yao Yao et al.